We are live on ! Find out more
LIMNW icon

Liminatus Pharma Warrants

24 hedge funds and large institutions have $95K invested in Liminatus Pharma Warrants in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.3% less ownership

Funds ownership: 34.12% → 31.82% (-2.3%)

8% less funds holding

Funds holding: 26 → 24 (-2)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

84% less capital inflows, than outflows

Capital inflows: $4.06K | Capital outflows: $24.7K

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
5
Closed
3
Calls
$2​K
Puts
–
Net Calls
+$2​K
Net Calls Change
-⁠$8​K

LIMNW Hedge Fund Activity: Q4 2025 in Review

24 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma Warrants (LIMNW) for Q4 2025, worth a combined $95K — down 76% from $400K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LIMNW and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $2.41K. The largest seller was Nomura Holdings, exiting entirely with an estimated $11.7K sold.

  • 24 institutional investors held Liminatus Pharma Warrants (LIMNW) as of Q4 2025, down from 26 in Q3 2025.
  • Funds reported $95K of Liminatus Pharma Warrants stock for Q4 2025, down 76% quarter-over-quarter.
  • 2 funds opened new Liminatus Pharma Warrants positions in Q4 2025 and 3 closed out, a net change of -1 holder.
  • The largest Liminatus Pharma Warrants buyer in Q4 2025 was Susquehanna International Group, an estimated $2.41K added.
  • The largest Liminatus Pharma Warrants seller in Q4 2025 was Nomura Holdings, an estimated $11.7K sold.

Based on aggregated 13F filings for Q4 2025.